Posted by Michael Wonder on 27 Oct 2015
Experience with the priority review voucher program for drug development
27 October 2015 - This viewpoint assesses the US Food and Drug Administration’s priority review voucher program to encourage development of drugs to treat neglected tropical diseases or rare pediatric disease and recommends improvements to the program.
For more details, go to: http://jama.jamanetwork.com/article.aspx?articleID=2448719&utm_source=Silverchair%20Information%20Systems&utm_medium=email&utm_campaign=MASTER%3AJAMALatestIssueTOCNotification10%2F27%2F2015
